Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Novo Nordisk A/S
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06285071CT.gov Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors | — | Enrolling By Invitation | — | — | — |
NCT04082429CT.gov Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors | — | Active Not Recruiting | — | — | — |
NCT04083781CT.gov Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03196284CT.gov A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia B
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Concizumab (this asset) | Novo Nordisk A/S | P3 | BB · 66 |
| Eptacog Alfa (Activated) | AryoGen Pharmed Co. | P4 | A |
| Factor Ix | CSL Behring | P4 | A |
| Nonacog Alfa | Pfizer | P4 | A |
| Nonacog Beta Pegol | Novo Nordisk A/S | P3 | A |
| Coagulation Factor Viia | American Thrombosis and Hemostasis Network | P4 | BBB |
| Albutrepenonacog Alfa | CSL Behring | P3 | BBB |
| Fitusiran | Genzyme, a Sanofi Company | P3 | BBB |
| Bax 326 | Baxalta now part of Shire | P3 | BB |
+40 more in the Hemophilia B cohort
Other indications for Concizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia A | — | P3 | BB · 68 |
| Inherited Blood Coagulation Disorder | — | P2 | BB · 64 |
| Hemophilia | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Concizumab in Hemophilia B. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/concizumab-hemophilia-b
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →